Get the Stockscreener App
13.66
8.81%
-1.32
Summit Therapeutics Inc stock is traded at $13.66, with a volume of 8.15M.
It is down -8.81% in the last 24 hours and down -4.14% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$14.98
Open:
$13.72
24h Volume:
8.15M
Relative Volume:
1.53
Market Cap:
$10.90B
Revenue:
$220.00K
Net Income/Loss:
$-1.21B
P/E Ratio:
-8.5167
EPS:
-1.6039
Net Cash Flow:
$-387.48M
1W Performance:
-1.09%
1M Performance:
-4.14%
6M Performance:
-17.16%
1Y Performance:
-50.45%
1-Day Range:
$13.20
$14.42
1-Week Range:
$13.20
$15.71
52-Week Range:
$12.55
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
13.66 | 10.90B | 220.00K | -1.21B | -387.48M | -1.6039 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Stifel | Buy |
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Dec-17-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-17-25 | Initiated | Barclays | Underweight |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Neutral |
| Jul-01-25 | Initiated | UBS | Buy |
| Jun-11-25 | Initiated | Leerink Partners | Underperform |
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
SMMT|Summit Therapeutics Inc|Price:13.660|Chg%:-1.320 - TradingKey
Summit Therapeutics (SMMT) Analyst Maintains Neutral Rating Afte - GuruFocus
SMMT Maintained by Guggenheim -- Price Target Lowered to $38.00 - GuruFocus
SMMT Maintained by Stifel -- Price Target Lowered to $38.00 - GuruFocus
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $29.2, Implies 95% Upside - TradingView
SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data - Stocktwits
Summit Therapeutics Flags Going Concern Risk Over Cash Needs - Benzinga
Summit Therapeutics Inc. Revenue Breakdown – NASDAQ:SMMT - TradingView
Stifel cuts Summit Therapeutics stock price target on timing concerns By Investing.com - Investing.com Canada
Summit Therapeutics (SMMT) Analyst Maintains Neutral Rating After Q2 Report - GuruFocus
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus - TradingView
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 - BioSpace
Guggenheim lowers Summit Therapeutics stock price target on trial timing By Investing.com - Investing.com Canada
Summit Therapeutics Signs Distribution Agreement With J.P. Morgan Securities for Common Stock Offering - Minichart
Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Marke - Benzinga
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Canada
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug - Yahoo Finance
Summit (SMMT) Completes Enrollment in Global HARMONi-3 Study - GuruFocus
Summit Q2 2026 slides: ivonescimab OS data strengthens amid spending rise - Investing.com Nigeria
Summit Therapeutics (SMMT) Reports Q2 EPS Beat with Strong Cash Position - GuruFocus
Summit Therapeutics (SMMT) Faces Financial Uncertainty Amid Funding Challenges - GuruFocus
Summit Therapeutics (SMMT) Reports Positive Clinical Developments and Strong Cash Position - GuruFocus
Summit Therapeutics Inc (SMMT) Q2 2026 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance UK
Summit Therapeutics Launches $380 Million At-the-Market Equity Offering Program with J.P. Morgan Securities - Kalkine Media
Summit Therapeutics Announces Q2 2026 Financial Results and Operational Highlights - Kalkine Media
Summit Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Summit (SMMT) Advances Clinical Trials with Promising Ivonescima - GuruFocus
Concerns Rise for Summit Therapeutics (SMMT) Regarding Financial Viability - GuruFocus
Summit Therapeutics (SMMT) Faces Funding Challenges Amid Q2 Losses - GuruFocus
Summit Therapeutics (SMMT) Updates Phase III Survival Data, Is The Stock Still A Bargain? - Yahoo Finance
SMMT Q2 FY2026 earnings call - finance.biggo.com
[SMMT Q2 2026 Earnings Call] Summit Therapeutics Cash Hits $690.7M, Updated HARMONi Data Shows HR 0.76 Overall Survival Ahead of PDUFA - finance.biggo.com
Summit Therapeutics Initiates $380 Million At-The-Market Stock Offering with J.P. Morgan - Kalkine Media
Earnings call transcript: Summit Therapeutics Q2 2026 loss widens as shares fall after hours - Investing.com Canada
SMMT: Summit Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Summit Therapeutics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:SMMT) 2026-07-23 - Seeking Alpha
Summit Therapeutics Q2 Earnings Call Highlights - Yahoo Finance
Transcript : Summit Therapeutics Inc., Q2 2026 Earnings Call, Jul 23, 2026 - marketscreener.com
Summit Therapeutics says cash crunch could impact its ability to continue - Seeking Alpha
Summit Therapeutics (SMMT) Q2 2026 earnings summary - Quartr
Summit Therapeutics Reports Ivonescimab Progress and Strong Cash - TipRanks
Summit Therapeutics (SMMT) sets up $380M at-the-market share offering - Stock Titan
Summit Therapeutics: substantial doubt about our ability to continue as a going concern - StreetInsider
Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q2 Adjusted Loss $0.19 per Share, vs. FactSet Est of $-0.17 - marketscreener.com
Summit Therapeutics (NASDAQ: SMMT) posts loss, eyes FDA decision - Stock Titan
Summit Therapeutics posts Q2 loss, reports ivonescimab trial data - StreetInsider
SMMT Reiterated by HC Wainwright & Co. -- Rating Maintained at N - GuruFocus
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study - Yahoo Finance
H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics By Investing.com - Investing.com Nigeria
Why (SMMT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics - Investing.com
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Summit Therapeutics Inc Stock (SMMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 12 '26 |
Buy |
13.12 |
3,810,000 |
49,987,200 |
573,883,879 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Soni Manmeet Singh | COO and CFO |
Jun 04 '26 |
Buy |
14.45 |
50,000 |
722,250 |
3,123,603 |
| Xia Yu | Director |
Oct 21 '25 |
Buy |
18.74 |
533,617 |
9,999,983 |
32,057,147 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):